This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 40893 results found since Jan 2013.

Dual-functionalized graphene oxide for enhanced siRNA delivery to breast cancer cells.
Abstract The aim of this study is to improve hydrocolloid stability and siRNA transfection ability of a reduced graphene oxide (rGO) based nano-carrier using a phospholipid-based amphiphilic polymer (PL-PEG) and cell penetrating peptide (CPPs). The dual functionalized nano-carrier is comprehensively characterized for its chemical structure, size, surface charge and morphology as well as thermal stability. The nano-carrier cytocompatibility, siRNA condensation ability both in the presence and absence of enzyme, endosomal buffering capacity, cellular uptake and intracellular localization are also assessed. The siRNA...
Source: Colloids and Surfaces - August 11, 2016 Category: Biotechnology Authors: Imani R, Shao W, Taherkhani S, Emami SH, Prakash S, Faghihi S Tags: Colloids Surf B Biointerfaces Source Type: research

Quantum dot ‐mediated delivery of siRNA to inhibit sphingomyelinase activities in brain‐derived cells
Abstract The use of RNAi to suppress protein synthesis offers a potential way of reducing the level of enzymes or the synthesis of mutant toxic proteins but there are few tools currently available for their delivery. To address this problem, bioconjugated quantum dots (QDs) containing a hydrophobic component (N‐palmitate) and a sequence VKIKK designed to traverse across cell membranes and visualize drug delivery were developed and tested on cell lines of brain origin. We used the Zn outer shell of the QD to bind HIS6 in JB577 (W•G•Dap(N‐Palmitoyl)•VKIKK•P9•G2•H6) and by a gel‐shift assay showed that siRNA...
Source: Journal of Neurochemistry - October 13, 2016 Category: Neuroscience Authors: Ted Getz, Jingdong Qin, Igor L. Medintz, James B. Delehanty, Kimihiro Susumu, Philip E. Dawson, Glyn Dawson Tags: Original Article Source Type: research

Preparation and In Vitro Evaluation of Vaginal Formulations Including siRNA and Paclitaxel-Loaded SLNs for Cervical Cancer.
This study indicate that vaginal suppository containing SLNs can bring the advantages of the simultaneous delivery of paclitaxel and siRNA via vaginal route with no help from professionals. PMID: 27793757 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutics and Biopharmaceutics - October 24, 2016 Category: Drugs & Pharmacology Authors: Büyükköroğlu G, Şenel B, Başaran E, Yenilmez E, Yazan Y Tags: Eur J Pharm Biopharm Source Type: research

Endocytic Transport of Polyplex and Lipoplex siRNA Vectors in HeLa Cells
ConclusionsMP, CvME and FME, but not the acidified clathrin-mediated pathway, lead to effective gene silencing by PEI/siRNA polyplexes. Lipoplexes, in contrast, deliver siRNA primarily by direct fusion of the liposomal and cellular membranes. These results provide a new understanding of the mechanisms of siRNA delivery materials in HeLa cells and may aid in design of more effective RNAi strategies.
Source: Pharmaceutical Research - November 3, 2016 Category: Drugs & Pharmacology Source Type: research

Bach1 siRNA attenuates bleomycin-induced pulmonary fibrosis by modulating oxidative stress in mice.
In this study, we knocked down Bach1 using adenovirus-mediated small interfering RNA (siRNA) to determine whether the use of Bach1 siRNA is an effective therapeutic strategy in mice with bleomycin (BLM)‑induced PF. Mouse lung fibroblasts (MLFs) were incubated with transforming growth factor (TGF)-β1 (5 ng/ml) and subsequently infected with recombined adenovirus-like Bach1 siRNA1 and Bach1 siRNA2, while an empty adenovirus vector was used as the negative control. The selected Bach1 siRNA with higher interference efficiency was used for the animal experiments. A mouse model of BLM-induced PF was established, and...
Source: International Journal of Molecular Medicine - December 7, 2016 Category: Molecular Biology Authors: Liu Y, Zheng Y Tags: Int J Mol Med Source Type: research

Anti-tumor effects of combined doxorubicin and siRNA for pulmonary delivery
In this study, combined doxorubicin (DOX) and Bcl2 siRNA was employed for cancer therapy using polyethylenimine (PEI) as the carrier of Bcl2 siRNA. Most of the DOX and siRNA possessed high cellular uptake efficiency in B16F10 cells, which was proved by FCM and CLSM analysis. Real-time PCR showed that PEI/Bcl2 siRNA exhibited high gene silencing efficiency with 70% Bcl2 mRNA being knocked down. The combination of DOX and siRNA could enhance the cell proliferation inhibition and the cell apoptosis against B16F10 cells compared to free DOX or PEI/Bcl2 siRNA. Furthermore, the biodistribution of DOX and siRNA via pulmonary admi...
Source: Chinese Chemical Letters - December 15, 2016 Category: Chemistry Source Type: research

Chitosan nanoparticle-delivered siRNA reduces CXCR4 expression and sensitizes breast cancer cells to cisplatin.
Abstract Chemokine (C-X-C motif) receptor 4 (CXCR4) has been reported as a poor prognotic biomarker in human breast cancers and has been suggested promising as a therapeutic target of breast cancer treatment. The present study aims to investigate the delivery efficiency of siRNA by chitosan into breast cancer cells, and then to examine the regulatory role by chitosan nanoparticle-delivered siRNA on CXCR4 expression and on the chemosensitivity of breast cancer cells. Our results demonstrated that the siRNA could be capsuled by chitosan into nanoparticles with a diameter of 80-110 nm, with a Zeta potential of 20-50 ...
Source: Bioscience Reports - April 26, 2017 Category: Biomedical Science Authors: Yu S, Chen Y, Li X, Gao Z, Liu G Tags: Biosci Rep Source Type: research

Enhanced delivery of biodegradable mPEG-PLGA-PLL nanoparticles loading Cy3-labelled PDGF-BB siRNA by UTMD to rat retina.
Abstract We investigated the efficacy and safety of ultrasound (US)-targeted microbubble (MB) destruction (UTMD)-enhanced delivery of monomethoxypoly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly-L-lysine (mPEG-PLGA-PLL) nanoparticles (NPs) loading Cy3-labelled platelet-derived growth factor BB (PDGF-BB) siRNA to rat retina in vivo. Eighty Wistar rats were divided into five groups (G). The right eyes, respectively, received an intravitreal injection as follows: normal saline (NS) (G1), NPs and NS (G2), NPs and MBs (G3), NPs and NS (G4) and NPs and MBs (G5). In G4 and G5, the eyes were exposed to US for 5 min...
Source: Journal of Biosciences - June 1, 2017 Category: Biomedical Science Authors: DU J, Sun Y, Li FH, DU LF, Duan YR Tags: J Biosci Source Type: research

Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: A review
Publication date: 1 September 2017 Source:Colloids and Surfaces B: Biointerfaces, Volume 157 Author(s): Mingfang Wang, Jinyu Wang, Bingcheng Li, Lingxin Meng, Zhaoxing Tian Co-delivery of chemotherapy drugs and siRNA for cancer therapy has achieved remarkable results according to synergistic/combined antitumor effects, and is recognized as a promising therapeutic modality. However, little attention has been paid to the extremely complex mechanisms of chemotherapy drug-siRNA pairs during co-delivery process. Proper selection of chemotherapy drug-siRNA pairs is beneficial for achieving desirable cancer therapeutic effects. ...
Source: Colloids and Surfaces B: Biointerfaces - June 12, 2017 Category: Biochemistry Source Type: research

Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes.
Abstract The aim of the present study was to evaluate the effectiveness of iontophoretic co-delivery of curcumin and anti-STAT3 siRNA using cationic liposomes against skin cancer. Curcumin was encapsulated in DOTAP-based cationic liposomes and then complexed with STAT3 siRNA. This nanocomplex was characterized for the average particle size, zeta-potential, and encapsulation efficiency. The cell viability studies in B16F10 mouse melanoma cells have shown that the co-delivery of curcumin and STAT3 siRNA significantly (p < 0.05) inhibited the cancer cell growth compared with either liposomal curcumin or STAT3 si...
Source: AAPS PharmSciTech - June 21, 2017 Category: Drugs & Pharmacology Authors: Jose A, Labala S, Ninave KM, Gade SK, Venuganti VVK Tags: AAPS PharmSciTech Source Type: research

Synthesis and characterization of amino acid-functionalized calcium phosphate nanoparticles for siRNA delivery
Publication date: 1 October 2017 Source:Colloids and Surfaces B: Biointerfaces, Volume 158 Author(s): Feray Bakan, Goknur Kara, Melike Cokol Cakmak, Murat Cokol, Emir Baki Denkbas Small interfering RNAs (siRNA) are short nucleic acid fragments of about 20–27 nucleotides, which can inhibit the expression of specific genes. siRNA based RNAi technology has emerged as a promising method for the treatment of a variety of diseases. However, a major limitation in the therapeutic use of siRNA is its rapid degradation in plasma and cellular cytoplasm, resulting in short half-life. In addition, as siRNA molecules cannot penetrate...
Source: Colloids and Surfaces B: Biointerfaces - July 8, 2017 Category: Biochemistry Source Type: research

Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route.
Authors: Meryet-Figuière M, Lecerf C, Varin E, Coll JL, Louis MH, Dutoit S, Giffard F, Blanc-Fournier C, Hedir S, Vigneron N, Brotin E, Pelletier L, Josserand V, Denoyelle C, Poulain L Abstract Ovarian cancer is the leading cause of death from gynecological malignancies worldwide, and innate or acquired chemoresistance of ovarian cancer cells is the major cause of therapeutic failure. It has been demonstrated that the concomitant inhibition of Bcl-xL and Mcl-1 anti-apoptotic activities is able to trigger apoptosis in chemoresistant ovarian cancer cells. In this context, siRNA-mediated Bcl‑xL and Mcl-1 inhibition...
Source: Oncology Reports - August 11, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Anti-oncogenic activities of cyclin D1b siRNA on human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and invasiveness.
Abstract The human cyclin D1 gene generates two major isoforms, cyclin D1a and cyclin D1b, by alternative splicing. Although cyclin D1b mRNA is hardly expressed in normal human tissues, it is detected in approximately 60% of human bladder cancer tissues and cell lines. In the present study, to assess the therapeutic ability of cyclin D1b siRNA, we investigated the anti-oncogenic effects of cyclin D1b siRNA on human bladder cancer cell lines, SBT31A and T24, which express cyclin D1b mRNA. Knockdown of cyclin D1b by specific siRNA significantly suppressed cell proliferation, in vitro cell invasiveness and th...
Source: International Journal of Oncology - November 7, 2017 Category: Cancer & Oncology Authors: Kim CJ, Terado T, Tambe Y, Mukaisho KI, Sugihara H, Kawauchi A, Inoue H Tags: Int J Oncol Source Type: research

Inhibition of HBV replication by delivering the dual-gene expression vector pHsa-miR16-siRNA in HepG2.2.15 cells
This study aimed to construct the dual-gene expression vector pHsa-miR16-siRNA which can express human miR-16 and HBV X siRNA, and examine its regulatory effect on HBV gene expression in the HepG2.2.15 cell line. The expression vectors siR-1583 and pHsa-miR16-siRNA were designed and constructed. HepG2.2.15 cells were transfected with the empty vector, siR-1583, pmiR-16 and pHsa-miR16-siRNA, respectively. ELISA was performed to measure the expression of HBsAg and HBeAg in the culture supernatant 48 and72 h post transfection. Fluorescence quantitative PCR was used to measure the HBV mRNA degradation efficiency and HBV DNA co...
Source: Journal of Huazhong University of Science and Technology -- Medical Sciences -- - December 1, 2017 Category: Research Source Type: research

PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Authors: Lai Y, Kong Z, Zeng T, Xu S, Duan X, Li S, Cai C, Zhao Z, Wu W Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib or rucaparib, have shown treatment efficacy in BRCA1/2-deficient tumors. However, since PARP inhibitors (PARPi) mainly modulate the activation of PARP but not its expression, whether small interfering RNA (siRNA) specific to PARP has the same function as PARPi has not been well defined. In the present study it was demonstrated that PARP1-siRNA could reduce prostate cancer (PCa) cell progression regardless of the BRCA1/2 mutation. PARP1 silencing could significantly inhibi...
Source: Oncology Reports - February 4, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research